Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver

Julius Chapiro, Rafael Duran, MingDe D. Lin, Rüdiger Schernthaner, David Lesage, Zhijun Wang, Lynn Jeanette Savic, Jean François Geschwind

Research output: Contribution to journalArticle

Abstract

Objectives: This study evaluated the predictive role of 1D, 2D and 3D quantitative, enhancement-based MRI regarding overall survival (OS) in patients with colorectal liver metastases (CLM) following intra-arterial therapies (IAT). Methods: This retrospective analysis included 29 patients who underwent transarterial chemoembolization (TACE) or radioembolization and received MRI within 6 weeks after therapy. Tumour response was assessed using 1D and 2D criteria (such as European Association for the Study of the Liver guidelines [EASL] and modified Response Evaluation Criteria in Solid Tumors [mRECIST]). In addition, a segmentation-based 3D quantification of overall (volumetric [v] RECIST) and enhancing lesion volume (quantitative [q] EASL) was performed on portal venous phase MRI. Accordingly, patients were classified as responders (R) and non-responders (NR). Survival was evaluated using Kaplan–Meier analysis and compared using Cox proportional hazard ratios (HR). Results: Only enhancement-based criteria identified patients as responders. EASL and mRECIST did not predict patient survival (P = 0.27 and P = 0.44, respectively). Using uni- and multivariate analysis, qEASL was identified as the sole predictor of patient survival (9.9 months for R, 6.9 months for NR; P = 0.038; HR 0.4). Conclusion: The ability of qEASL to predict survival early after IAT provides evidence for potential advantages of 3D quantitative tumour analysis. Key Points: • Volumetric assessment of colorectal liver metastases after intra-arterial therapy is feasible. • Early 3D quantitative tumour analysis after intra-arterial therapy may predict patient survival. • Volumetric tumour response assessment shows advantages over 1D and 2D techniques. • Enhancement-based MR response assessment is preferable to size-based measurements.

Original languageEnglish (US)
Pages (from-to)1993-2003
Number of pages11
JournalEuropean Radiology
Volume25
Issue number7
DOIs
StatePublished - Jul 8 2015

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Survival
Liver
Neoplasms
Therapeutics
Multivariate Analysis
Guidelines
Response Evaluation Criteria in Solid Tumors

Keywords

  • Chemoembolization
  • Colorectal cancer
  • Liver cancer
  • Magnetic resonance imaging
  • Metastases

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Early survival prediction after intra-arterial therapies : a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. / Chapiro, Julius; Duran, Rafael; Lin, MingDe D.; Schernthaner, Rüdiger; Lesage, David; Wang, Zhijun; Savic, Lynn Jeanette; Geschwind, Jean François.

In: European Radiology, Vol. 25, No. 7, 08.07.2015, p. 1993-2003.

Research output: Contribution to journalArticle

Chapiro, Julius ; Duran, Rafael ; Lin, MingDe D. ; Schernthaner, Rüdiger ; Lesage, David ; Wang, Zhijun ; Savic, Lynn Jeanette ; Geschwind, Jean François. / Early survival prediction after intra-arterial therapies : a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. In: European Radiology. 2015 ; Vol. 25, No. 7. pp. 1993-2003.
@article{686b5652ee6c409faf70801015143d83,
title = "Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver",
abstract = "Objectives: This study evaluated the predictive role of 1D, 2D and 3D quantitative, enhancement-based MRI regarding overall survival (OS) in patients with colorectal liver metastases (CLM) following intra-arterial therapies (IAT). Methods: This retrospective analysis included 29 patients who underwent transarterial chemoembolization (TACE) or radioembolization and received MRI within 6 weeks after therapy. Tumour response was assessed using 1D and 2D criteria (such as European Association for the Study of the Liver guidelines [EASL] and modified Response Evaluation Criteria in Solid Tumors [mRECIST]). In addition, a segmentation-based 3D quantification of overall (volumetric [v] RECIST) and enhancing lesion volume (quantitative [q] EASL) was performed on portal venous phase MRI. Accordingly, patients were classified as responders (R) and non-responders (NR). Survival was evaluated using Kaplan–Meier analysis and compared using Cox proportional hazard ratios (HR). Results: Only enhancement-based criteria identified patients as responders. EASL and mRECIST did not predict patient survival (P = 0.27 and P = 0.44, respectively). Using uni- and multivariate analysis, qEASL was identified as the sole predictor of patient survival (9.9 months for R, 6.9 months for NR; P = 0.038; HR 0.4). Conclusion: The ability of qEASL to predict survival early after IAT provides evidence for potential advantages of 3D quantitative tumour analysis. Key Points: • Volumetric assessment of colorectal liver metastases after intra-arterial therapy is feasible. • Early 3D quantitative tumour analysis after intra-arterial therapy may predict patient survival. • Volumetric tumour response assessment shows advantages over 1D and 2D techniques. • Enhancement-based MR response assessment is preferable to size-based measurements.",
keywords = "Chemoembolization, Colorectal cancer, Liver cancer, Magnetic resonance imaging, Metastases",
author = "Julius Chapiro and Rafael Duran and Lin, {MingDe D.} and R{\"u}diger Schernthaner and David Lesage and Zhijun Wang and Savic, {Lynn Jeanette} and Geschwind, {Jean Fran{\cc}ois}",
year = "2015",
month = "7",
day = "8",
doi = "10.1007/s00330-015-3595-5",
language = "English (US)",
volume = "25",
pages = "1993--2003",
journal = "European Radiology",
issn = "0938-7994",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Early survival prediction after intra-arterial therapies

T2 - a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver

AU - Chapiro, Julius

AU - Duran, Rafael

AU - Lin, MingDe D.

AU - Schernthaner, Rüdiger

AU - Lesage, David

AU - Wang, Zhijun

AU - Savic, Lynn Jeanette

AU - Geschwind, Jean François

PY - 2015/7/8

Y1 - 2015/7/8

N2 - Objectives: This study evaluated the predictive role of 1D, 2D and 3D quantitative, enhancement-based MRI regarding overall survival (OS) in patients with colorectal liver metastases (CLM) following intra-arterial therapies (IAT). Methods: This retrospective analysis included 29 patients who underwent transarterial chemoembolization (TACE) or radioembolization and received MRI within 6 weeks after therapy. Tumour response was assessed using 1D and 2D criteria (such as European Association for the Study of the Liver guidelines [EASL] and modified Response Evaluation Criteria in Solid Tumors [mRECIST]). In addition, a segmentation-based 3D quantification of overall (volumetric [v] RECIST) and enhancing lesion volume (quantitative [q] EASL) was performed on portal venous phase MRI. Accordingly, patients were classified as responders (R) and non-responders (NR). Survival was evaluated using Kaplan–Meier analysis and compared using Cox proportional hazard ratios (HR). Results: Only enhancement-based criteria identified patients as responders. EASL and mRECIST did not predict patient survival (P = 0.27 and P = 0.44, respectively). Using uni- and multivariate analysis, qEASL was identified as the sole predictor of patient survival (9.9 months for R, 6.9 months for NR; P = 0.038; HR 0.4). Conclusion: The ability of qEASL to predict survival early after IAT provides evidence for potential advantages of 3D quantitative tumour analysis. Key Points: • Volumetric assessment of colorectal liver metastases after intra-arterial therapy is feasible. • Early 3D quantitative tumour analysis after intra-arterial therapy may predict patient survival. • Volumetric tumour response assessment shows advantages over 1D and 2D techniques. • Enhancement-based MR response assessment is preferable to size-based measurements.

AB - Objectives: This study evaluated the predictive role of 1D, 2D and 3D quantitative, enhancement-based MRI regarding overall survival (OS) in patients with colorectal liver metastases (CLM) following intra-arterial therapies (IAT). Methods: This retrospective analysis included 29 patients who underwent transarterial chemoembolization (TACE) or radioembolization and received MRI within 6 weeks after therapy. Tumour response was assessed using 1D and 2D criteria (such as European Association for the Study of the Liver guidelines [EASL] and modified Response Evaluation Criteria in Solid Tumors [mRECIST]). In addition, a segmentation-based 3D quantification of overall (volumetric [v] RECIST) and enhancing lesion volume (quantitative [q] EASL) was performed on portal venous phase MRI. Accordingly, patients were classified as responders (R) and non-responders (NR). Survival was evaluated using Kaplan–Meier analysis and compared using Cox proportional hazard ratios (HR). Results: Only enhancement-based criteria identified patients as responders. EASL and mRECIST did not predict patient survival (P = 0.27 and P = 0.44, respectively). Using uni- and multivariate analysis, qEASL was identified as the sole predictor of patient survival (9.9 months for R, 6.9 months for NR; P = 0.038; HR 0.4). Conclusion: The ability of qEASL to predict survival early after IAT provides evidence for potential advantages of 3D quantitative tumour analysis. Key Points: • Volumetric assessment of colorectal liver metastases after intra-arterial therapy is feasible. • Early 3D quantitative tumour analysis after intra-arterial therapy may predict patient survival. • Volumetric tumour response assessment shows advantages over 1D and 2D techniques. • Enhancement-based MR response assessment is preferable to size-based measurements.

KW - Chemoembolization

KW - Colorectal cancer

KW - Liver cancer

KW - Magnetic resonance imaging

KW - Metastases

UR - http://www.scopus.com/inward/record.url?scp=84930474400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930474400&partnerID=8YFLogxK

U2 - 10.1007/s00330-015-3595-5

DO - 10.1007/s00330-015-3595-5

M3 - Article

C2 - 25636420

AN - SCOPUS:84930474400

VL - 25

SP - 1993

EP - 2003

JO - European Radiology

JF - European Radiology

SN - 0938-7994

IS - 7

ER -